Filing scope and business context
The supplied document is NantKwest, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019 (ticker NK), filed May 8, 2019. It is not filed under the ImmunityBio name; this summary reflects the issuer identified in the filing. NantKwest was a clinical-stage immunotherapy biotechnology company developing natural-killer-cell therapies for cancer and viral infections. It had no approved products and no product-sales revenue.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are unaudited and in millions unless noted.
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | $0.005 | $0.005 |
| Research and development | $12.6 | $14.0 |
| Selling, general and administrative | $5.7 | $14.3 |
| Total operating expenses | $18.3 | $28.3 |
| Net loss | $17.9 | $27.5 |
| Net loss per share, basic and diluted | $0.22 | $0.35 |
| Cash used in operating activities | $13.1 | $15.5 |
| Cash, cash equivalents and restricted cash at quarter-end | $23.7 | $11.4 |
| Marketable debt securities at quarter-end | $80.5 | $125.7 at March 31, 2018 |
At March 31, 2019, total assets were $208.3 million, current assets $113.4 million, current liabilities $27.7 million, total liabilities $40.5 million, and stockholders’ equity $167.8 million. The company reported an accumulated deficit of $613.8 million. It had no material conventional debt reported; operating lease liabilities totaled approximately $15.7 million, following adoption of the new lease accounting standard.
Changes versus the prior comparable period
- Net loss narrowed by $9.6 million (35%), while operating expenses fell $9.9 million (35%).
- SG&A declined $8.6 million, mainly because Q1 2018 included $7.6 million of stock compensation tied to CEO awards that had completed vesting by July 2018. R&D declined $1.4 million, partly due to lower staffing, shared-service and trial activity; facility and manufacturing costs partly offset those reductions.
- Operating cash use improved by $2.4 million. Investing activities used $19.5 million in Q1 2019, versus providing $2.9 million in Q1 2018, largely reflecting timing of purchases and maturities of marketable securities.
- Cash and restricted cash increased by $6.7 million during the quarter, mainly from $39.2 million of proceeds from warrant and stock-option exercises, offset by operating and investing outflows.
- Common shares outstanding rose from 79.1 million at year-end 2018 to 98.7 million at March 31, 2019. The CEO exercised warrants for 17.6 million shares and options for approximately 2.0 million shares.
Outlook, risks and unusual items
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operating and capital requirements for at least 12 months after issuance of the financial statements. The estimate depends on assumptions that could prove incorrect; additional financing may be needed, and no external funding source was committed.
- Management expected R&D expense to increase significantly as development and clinical trials advanced; SG&A for 2019 was expected to remain relatively consistent with the prior year. The company did not expect product revenue for at least several years, if ever, and could not estimate the cost or timing of completing product development.
- FDA authorization had been obtained for multiple investigational studies using cryopreserved haNK cells, including as part of the Nant Cancer Vaccine regimen. These were development-stage programs, not approvals to market products.
- A proposed $12.0 million securities-litigation settlement was subject to court approval; the company’s stated share was $1.2 million, with $10.8 million funded by insurers. A separate proposed stockholder settlement required governance changes and a $0.5 million attorney fee, half payable by the company and half expected to be insurer-funded. The filing reported a final hearing for the securities settlement on April 29, 2019, but does not provide the outcome.
- Adoption of the lease standard on January 1, 2019 recognized $13.5 million of right-of-use assets and $16.4 million of lease liabilities at adoption; the $0.9 million cumulative adjustment increased accumulated deficit. Adoption did not materially affect operations or cash flows.
- Key risks include clinical and regulatory failure, manufacturing scale-up and supply constraints, competition, further financing and dilution needs, and dependence on affiliates and related parties. The CEO and affiliates controlled approximately 67.1% of common shares at quarter-end. Management reported disclosure controls effective at a reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Confirm the issuer and filing identity: the supplied 10-Q names NantKwest, Inc., not ImmunityBio, Inc.
- Check subsequent cash use, securities balances, financing activity and whether the stated 12-month runway assumptions held.
- Review subsequent clinical-trial progress, enrollment, safety findings, FDA interactions and manufacturing readiness for haNK, taNK and t-haNK programs.
- Verify court approval and final payment terms for both proposed settlements, including the company’s net costs and insurance recoveries.
- Assess the dilution and governance implications of the CEO’s share exercises, concentrated voting control and related-party arrangements.